Liraglutide
Liraglutide (Victoza, Saxenda): approved uses, label warnings and how it compares with newer GLP-1 drugs.
FDA-approved · Evidence grade A · Reviewed
Liraglutide (Victoza, Saxenda). GLP-1 receptor agonist.
AFDA-approved. Evidence grade A: approved, large human trials.
What is Liraglutide?
Liraglutide is an earlier GLP-1 drug, given as a daily injection. Newer weekly drugs have largely overtaken it.
Is Liraglutide FDA-approved?
Approved as Victoza for type 2 diabetes and as Saxenda for chronic weight management, including in adolescents aged 12 and over.
What does the evidence show for Liraglutide?
Large human trials and more than a decade of real-world use.
What are the known risks of Liraglutide?
The label carries a boxed warning about thyroid C-cell tumors, based on rodent studies. It is not known whether the same happens in people. The most common side effects are nausea, vomiting, diarrhea, constipation and stomach pain. Labels for this class also warn about pancreatitis. Cases of medullary thyroid cancer have been reported in people taking liraglutide since it came to market.
How is Liraglutide measured?
Supplied as pre-measured pens, so there is nothing to calculate.
Sources: Novo Nordisk: Wegovy and Saxenda safety information; Ro: GLP-1 safety information. This profile does not recommend any dose or use.
For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.